Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2020

View Archived Issues

Novel variant linked to childhood steroid-sensitive nephrotic syndrome

HanaVax, University of Tokyo present mutated Pneumococcal surface proteins

New CD73 inhibitors synthesized at Eternity Bioscience

J2H Biotech, Ahn-Gook Pharmaceutical describe new mirabegron prodrugs

University of Florida identifies new PRMT5 inhibitors

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical patent ERK-1/2 inhibitors

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Global phase III PolarisDMD trial of edasalonexent does not meet primary endpoint

XL-092: a promising pan-tyrosine kinase inhibitor in clinical development

First patient enrolled in the immune modulation domain of REMAP-COVID substudy

Prilenia initiates enrollment in phase III PROOF-HD trial of pridopidine

New phase I/Ib study to evaluate GEN-001 with avelumab for solid tumors

Positive 6-month interim analysis data presented from TOPAZ phase II study of SRK-015

Alzheon studies ALZ-801 in phase II biomarker study for early Alzheimer's

UKRI conditionally approves grant funding to explore SDC-1801 as treatment of COVID-19

SIMR-1281: a novel candidate for clinical trials in cancer

ASHG 2020: New inflammatory disease, and maybe, a new classification system

First-in-human data presented for TPX-0022

FDA clears IND for phase Ib study of bempegaldesleukin for COVID-19

Spero Therapeutics' SPR-720 shows promise in phase I study

Voclosporin studied for antiviral effects in kidney transplant recipients with COVID-19

Apollomics reports phase I data for APL-101

FDA approves Eysuvis for short-term treatment of dry eye disease

Valo Therapeutics describes design and preclinical results with neoantigen-coated oncolytic viruses

Novel selective TRK degraders effectively reduce TPM3-TRKA fusion protein levels

New pilot study to evaluate afamelanotide for arterial ischemic stroke

Histogen and Amerimmune collaborate to study emricasan for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...